Centogene Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>CE</div>
CNTG -- USA Stock  

USD 11.55  0.31  2.76%

Whilst many millenniums are getting more into healthcare space, it makes sense to digest Centogene NV against current trends within the economy. As we have suggested previously, Centogene is beginning its dip as shareholders shift to be more bearish due to the increased sector volatility. The returns on investing in Centogene and the market returns of the last few months appear uncorrelated. Unsteady basic indicators of the firm may also indicate signs of longer-term losses for Centogene shareholders. Centogene NV is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 21st of September 2020.
Published over three months ago
View all stories for Centogene | View All Stories
Planning to continue with Centogene NV (NASDAQ:CNTG) in October?
This firm's average rating is Buy from 5 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Centogene market sentiment investors' perception of the future value of Centogene. Let us look at a few aspects of Centogene technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Centogene NV. In general, we focus on analyzing Centogene stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Centogene's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Centogene's intrinsic value. In addition to deriving basic predictive indicators for Centogene, we also check how macroeconomic factors affect Centogene price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Centogene's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Centogene in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Centogene. Your research has to be compared to or analyzed against Centogene's peers to derive any actionable benefits. When done correctly, Centogene's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Centogene NV.

How does Centogene Stands against Peers?

Analyzing Centogene competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Centogene across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Centogene Competition Details

How Centogene utilizes its cash?

To perform a cash flow analysis of Centogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Centogene is receiving and how much cash it distributes out in a given period. The Centogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Centogene Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (7 Million)

A Deeper look at Centogene

The company has a beta of 0.0212. Let's try to break down what Centogene's beta means in this case. The returns on MARKET and Centogene are completely uncorrelated. The beta indicator helps investors understand whether Centogene moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Centogene deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Centogene NV reported the previous year's revenue of 47.18 M. Net Loss for the year was (21.2 M) with profit before overhead, payroll, taxes, and interest of 22.77 M.

Centogene price dip is confusing

Latest maximum drawdown is at 35.13. Centogene NV exhibits very low volatility with skewness of -0.83 and kurtosis of 4.19. However, we advise investors to further study Centogene NV technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Centogene

Although many other companies in the diagnostics & research industry are either recovering or due for a correction, Centogene may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Centogene valuation and our trade advice on Centogene is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Centogene.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Centogene NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com